-transparent.png){kind=logo}
Evaluation of new therapies for the inflammatory myopathies is complicated by the heterogeneity of these syndromes as well as by the lack of internationally accepted definitions of disease categories and assessments of disease activity and chronicity. This review covers our opinion of therapies and emphasizes the need for an early rehabilitation evaluation for these patients. Oral corticosteroids are the first line of therapy for the inflammatory myopathies, but because of their side effects and the existence of a subset of patients in whom disease is controlled only with high-dose corticosteroids, we recommend considering the early use of a second-line immunomodulating agents or pulse intravenous methylprednisolone. A stepwise progression of therapies is suggested for patients who have increasing muscle weakness resulting from active disease.
L Villalba, and
E M Adams
May 2006,
The Journal of rheumatology,
L Villalba, and
E M Adams
August 1987,
The Australasian journal of dermatology,
L Villalba, and
E M Adams
January 1977,
Advances in neurology,
L Villalba, and
E M Adams
June 2006,
Current rheumatology reports,
L Villalba, and
E M Adams
June 2008,
La Revue de medecine interne,
L Villalba, and
E M Adams
January 2009,
Lung,
L Villalba, and
E M Adams
January 2013,
Reumatologia clinica,
L Villalba, and
E M Adams
February 2000,
International journal of dermatology,
L Villalba, and
E M Adams
October 2007,
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
L Villalba, and
E M Adams
November 2011,
Autoimmunity reviews,
